DCF — NEWARK BETH ISRAEL MEDICAL CENTER
Enterprise Value: $-977.6M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-977.6M
Enterprise Value
$-311.9M
PV of Cash Flows
$-665.7M
PV of Terminal Value
$-1.1B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $690.0M | $-59.5M | -9.0% | $-88.7M | $-80.6M |
| Year 2 | $710.7M | $-54.1M | -8.0% | $-84.2M | $-69.6M |
| Year 3 | $732.0M | $-48.4M | -7.0% | $-79.4M | $-59.7M |
| Year 4 | $754.0M | $-46.1M | -6.0% | $-78.0M | $-53.3M |
| Year 5 | $776.6M | $-45.6M | -6.0% | $-78.4M | $-48.7M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-977.6M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$669.9M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.09118147898945883
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5